| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 09/16/1999 | CA2322472A1 Delivery system to modulate immune response |
| 09/16/1999 | CA2321026A1 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 09/15/1999 | EP0941999A2 Preparation of azithromycin dihydrate |
| 09/15/1999 | EP0941998A2 3,6-ketal and enol ether macrolide antibiotics |
| 09/15/1999 | EP0941738A1 Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria |
| 09/15/1999 | EP0941337A1 Synthesis and purification of hepatitis c virus-like particles |
| 09/15/1999 | EP0941336A2 Papilloma viruses, agents for detecting the same and for treating diseases caused by such viruses |
| 09/15/1999 | EP0941335A2 Streptococcus pneumoniae polynucleotides and sequences |
| 09/15/1999 | EP0941333A1 Immunogenic detoxified mutant e. coli lt-a toxin |
| 09/15/1999 | EP0941321A1 Circularly permuted polypeptides as novel stem cell factor receptor agonists |
| 09/15/1999 | EP0941241A1 $i(BORDETELLA) STRAIN EXPRESSING THE FHA HYBRID, LIPOSOMES AND VACCINES |
| 09/15/1999 | EP0941240A1 New picornaviruses, vaccines and diagnostic kits |
| 09/15/1999 | EP0941237A1 Cyclic hexapeptides having antibiotic activity |
| 09/15/1999 | EP0941236A1 Cyclohexapeptides having antimicrobial activity |
| 09/15/1999 | EP0941233A2 Antiviral peptide derivatives |
| 09/15/1999 | EP0941229A1 Purification of fermented clavulanic acid |
| 09/15/1999 | EP0941122A2 Compositions and methods for polynucleotide delivery |
| 09/15/1999 | EP0941100A2 Pharmaceutical compositions containing lamivudine and zidovudine |
| 09/15/1999 | EP0941087A1 Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections |
| 09/15/1999 | EP0910460A4 Iodinated matrices for disinfecting biological fluids |
| 09/15/1999 | EP0799188B1 Amides of mono and dicarboxylic acids with glycosamines, selectively active on the cannabinoid peripheral receptor |
| 09/15/1999 | EP0759899B1 Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities |
| 09/15/1999 | EP0749421B1 Sulphonamide derivatives as aspartyl protease inhibitors |
| 09/15/1999 | EP0748383B1 Targeted cleavage of rna using ribonuclease p targeting and cleavage sequences |
| 09/15/1999 | EP0679194B1 Method to predict active growth of bacteria adhered to a surface |
| 09/15/1999 | EP0644883B1 Enniatines and enniatine derivates used to control endoparasites |
| 09/15/1999 | EP0641339B1 Azaspiro quinolone antibacterial agents |
| 09/15/1999 | EP0611304B1 Use of acetylated mannan (acemannan) for the regulation of blood cholesterol levels and for removing plaques in blood vessels |
| 09/15/1999 | EP0567470B1 Pseudomonas peptide composition and method for producing the same |
| 09/15/1999 | CN1228779A Spirocyclic metalloprotease inhibitors |
| 09/15/1999 | CN1228773A Heterocyclic metalloprotease inhibitors |
| 09/15/1999 | CN1228709A Multivalent DTP-POLID vaccines |
| 09/15/1999 | CN1228699A Antifungal composition with enhanced bioavailability |
| 09/15/1999 | CN1228697A Method for in vivo reduction of iron levels and compositions useful therefor |
| 09/15/1999 | CN1228696A Use of PKC inhibitors for manufacture of medicament for treatment of AIDS |
| 09/15/1999 | CN1228693A Oral composition comprising triazole antifungal compound |
| 09/15/1999 | CN1228678A Improved method for systemic administration of 2,4-dienoic acid-type insecticides to terrestrial mammals |
| 09/15/1999 | CN1228422A Process for preparing naphthyridones and intermediates |
| 09/15/1999 | CN1045089C 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1, 3-propanediol derivative |
| 09/15/1999 | CN1045088C Purine and guanine compounds as inhibitors of PNP |
| 09/14/1999 | US5952502 Administering to the mammal a dioxolane compound for fungal treatment |
| 09/14/1999 | US5952500 Nucleoside derivatives |
| 09/14/1999 | US5952499 Therapeutic compound-fatty acid conjugates |
| 09/14/1999 | US5952490 Oligonucleotides having a conserved G4 core sequence |
| 09/14/1999 | US5952483 Human IκB-β |
| 09/14/1999 | US5952478 Nucleotides and analogs in which both the 3' oxy linkage and the 5' oxy linkage are replaced by carbon linkages; for antisense agents; viricides against influenza, herpes and human immune deficiency virus; anticarcinogenic agents |
| 09/14/1999 | US5952466 Reductive alkylation of glycopeptide antibiotics |
| 09/14/1999 | US5952382 Inhibiting the biological effects of an overregulation of retinoid acid receptors and/or of a hypervitaminosis a; treating skin disorder, eye vision defects, skin aging |
| 09/14/1999 | US5952375 Compounds and methods for synthesis and therapy |
| 09/14/1999 | US5952343 HIV protease inhibitors |
| 09/14/1999 | US5952334 Carbocyclic compounds |
| 09/14/1999 | US5952324 Bicyclic oxazine and thiazine oxazolidinone antibacterials |
| 09/14/1999 | US5952318 Treatment of HIV positive patients |
| 09/14/1999 | US5952311 Photosensitizing chemical means for killing tumor cells, wherein tumoricidal activity is activated by absorbing light or energy within a specific wavelength range, and energy donating chemical means for activating photosensitizer |
| 09/14/1999 | US5952310 Bactericides |
| 09/14/1999 | US5952302 Human therapeutic uses of BPI protein products |
| 09/14/1999 | US5952299 Cyclic peptide nuclei and derivatives thereof |
| 09/14/1999 | US5952232 Expandible microparticle intracellular delivery system |
| 09/14/1999 | US5952002 Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor |
| 09/14/1999 | US5951987 Polysaccharide vaccine to enhance immunity against brucellosis |
| 09/14/1999 | US5951986 Tandem synthetic HIV-1 peptides |
| 09/14/1999 | US5951976 Vaccinating a mammal by administering a composition comprising an opsonin-enhanced cell comprising said selected antigen with the provision the opsonin does not bind to a receptor for a fragment of c33 |
| 09/14/1999 | US5951974 At least about 15%, preferably about 30%, of the interferon conjugates have a nonantigenic alkylpolyether attached to a preferential histidine residue; high activity; reacting an n-oxycarbonyloxyimide at acidic ph |
| 09/14/1999 | CA2132208C Method of eliminating inhibitory/instability regions of mrna |
| 09/14/1999 | CA2071446C Synthetic catalytic oligonucleotide structures |
| 09/14/1999 | CA1340734C Substituted bridged-diazabicycloalkyl quinolone carboxylic acids |
| 09/13/1999 | CA2265412A1 Process for the preparation of azithromycin dihydrate |
| 09/10/1999 | WO1999045104A2 Purification of virus preparations |
| 09/10/1999 | WO1999045102A1 Method for activating natural killer (nk) cells |
| 09/10/1999 | WO1999045098A2 Delivery or proteins into eukaryotic cells with recombinant yersinia |
| 09/10/1999 | WO1999045027A1 Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes |
| 09/10/1999 | WO1999045025A1 Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| 09/10/1999 | WO1999045024A1 Cholenic acid amides and pharmaceutical compositions thereof |
| 09/10/1999 | WO1999045016A2 Novel prodrugs for phosphorus-containing compounds |
| 09/10/1999 | WO1999045010A1 Process for synthesizing carbapenem antibiotics |
| 09/10/1999 | WO1999044991A1 Process for preparing a protected 4-aminomethyl-pyrrolidin-3-one |
| 09/10/1999 | WO1999044640A1 Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor |
| 09/10/1999 | WO1999044635A1 Enhancement of immunity by intranasal inoculation of il-12 |
| 09/10/1999 | WO1999044634A1 Il-12 stimulation of neonatal immunity |
| 09/10/1999 | WO1999044633A1 Live recombined vaccines injected with adjuvant |
| 09/10/1999 | WO1999044629A2 Utilization of cd137 in order to promote the proliferation of peripheral monocytes |
| 09/10/1999 | WO1999044622A1 Inorganic nitrite and organic acid in combination as topical antiviral composition |
| 09/10/1999 | WO1999044619A1 Treatment of viral disease in swine |
| 09/10/1999 | WO1999044616A1 Steroid derived antibiotics |
| 09/10/1999 | WO1999044614A1 Pharmaceutical composition containing cefuroxime axetil stable for moisture absorption |
| 09/10/1999 | WO1999044608A1 New use |
| 09/10/1999 | WO1999044605A1 Use of pkc inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection |
| 09/10/1999 | WO1999044604A1 Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate |
| 09/10/1999 | WO1999044584A1 Emulsion preconcentrates containing cyclosporin or a macrolide |
| 09/10/1999 | WO1999044578A1 Formulations with an anti-viral effect |
| 09/10/1999 | WO1999044440A1 Food compositions for preventing periodontosis or preventing the progression of periodontosis and method for preventing or treating periodontosis |
| 09/10/1999 | WO1999044425A1 Fungicide composition comprising a benzoylphenylurea |
| 09/10/1999 | WO1999033850A8 NOVEL β-LACTAMASE AND DD-PEPTIDASE INHIBITORS |
| 09/10/1999 | WO1999033793A3 Prodrugs of aspartyl protease inhibitors |
| 09/10/1999 | WO1999031262A3 Needle-free injection of formulated nucleic acid molecules |
| 09/10/1999 | WO1999027958A9 Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination |
| 09/10/1999 | CA2323158A1 Use of pkc inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection |
| 09/10/1999 | CA2322838A1 Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes |
| 09/10/1999 | CA2322796A1 Pharmaceutical compositions containing the phospholipase inhibitor sodium ¬¬3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl|oxy|acetate |
| 09/10/1999 | CA2322712A1 Method for activating natural killer (nk) cells |